全文获取类型
收费全文 | 9256篇 |
免费 | 532篇 |
国内免费 | 68篇 |
专业分类
耳鼻咽喉 | 44篇 |
儿科学 | 207篇 |
妇产科学 | 191篇 |
基础医学 | 973篇 |
口腔科学 | 176篇 |
临床医学 | 979篇 |
内科学 | 2172篇 |
皮肤病学 | 156篇 |
神经病学 | 501篇 |
特种医学 | 232篇 |
外国民族医学 | 1篇 |
外科学 | 1732篇 |
综合类 | 219篇 |
现状与发展 | 1篇 |
一般理论 | 5篇 |
预防医学 | 556篇 |
眼科学 | 157篇 |
药学 | 855篇 |
中国医学 | 161篇 |
肿瘤学 | 538篇 |
出版年
2024年 | 16篇 |
2023年 | 179篇 |
2022年 | 543篇 |
2021年 | 680篇 |
2020年 | 411篇 |
2019年 | 493篇 |
2018年 | 503篇 |
2017年 | 300篇 |
2016年 | 341篇 |
2015年 | 367篇 |
2014年 | 442篇 |
2013年 | 513篇 |
2012年 | 812篇 |
2011年 | 741篇 |
2010年 | 355篇 |
2009年 | 332篇 |
2008年 | 522篇 |
2007年 | 483篇 |
2006年 | 407篇 |
2005年 | 382篇 |
2004年 | 322篇 |
2003年 | 284篇 |
2002年 | 150篇 |
2001年 | 47篇 |
2000年 | 38篇 |
1999年 | 22篇 |
1998年 | 23篇 |
1997年 | 11篇 |
1996年 | 13篇 |
1995年 | 9篇 |
1994年 | 9篇 |
1993年 | 10篇 |
1992年 | 10篇 |
1991年 | 9篇 |
1990年 | 4篇 |
1989年 | 5篇 |
1988年 | 7篇 |
1987年 | 3篇 |
1985年 | 6篇 |
1984年 | 7篇 |
1983年 | 3篇 |
1982年 | 6篇 |
1981年 | 12篇 |
1980年 | 3篇 |
1978年 | 5篇 |
1977年 | 3篇 |
1976年 | 3篇 |
1975年 | 2篇 |
1972年 | 3篇 |
1969年 | 2篇 |
排序方式: 共有9856条查询结果,搜索用时 15 毫秒
121.
Khan MI Hussain M Jamil M Arif M Raza A Chaudhary MA 《Journal of the College of Physicians and Surgeons--Pakistan : JCPSP》2005,15(2):123-124
Carcinoma of the lip is a common cancer of head and neck area. It occurs frequently on the lower lip of middle-aged and elderly males who have a history of chronic sun exposure. Surgical excision and radiotherapy are regarded as equally effective treatment options, but preferred method is surgical excision. Karapandzic technique provides myoneurovascular pedicled advancement flap for reconstruction of the defect after surgical excision. It is a simple and safe technique, functionally and esthetically, sacrifices little tissue, heals rapidly and is effective for repair of defects covering 1/3 to 4/5 of the lower lip. We report a 62 years male who presented with a large, fungating, pus-discharging and tender mass of lower lip. Biopsy confirmed squamous cell carcinoma. Tumor was excised and defect was reconstructed using Karapandzic technique. Patient remained asymptomatic during follow-up visits. 相似文献
122.
123.
Teoh CM Rohaizak M Chan KY Jasmi AY Fuad I 《Asian journal of surgery / Asian Surgical Association》2005,28(2):90-96
OBJECTIVE: This study reviewed the incidence of positive pre-ablative diagnostic scan after total thyroidectomy and the efficacy of the current ablative dose. The predictive factors for outcome using a standard ablative dose and postoperative complications of total thyroidectomy were also examined. METHODS: This was a retrospective review of patients referred for radioiodine ablation after total thyroidectomy between September 1997 and September 2001. RESULTS: Forty patients were included in this study, of whom 95% had a positive scan after total thyroidectomy. Of the 30 patients who underwent standard 80-mCi radioiodine ablation, 21 (70%) had successful single ablation while the remaining nine patients needed a higher ablative dose. There were no significant differences between patients who had successful ablation with the standard dose and those who did not in terms of tumour size, patient age, lymph node status and extra-thyroidal extension. Fifteen percent suffered from permanent hypoparathyroidism requiring calcium supplementation. Three patients had documented recurrent laryngeal nerve paralysis. CONCLUSION: Bypassing the pre-ablative diagnostic scan is feasible. The present ablation dose of 80 mCi of radioiodine is effective. The relatively high postoperative morbidity after difficult total thyroidectomy suggests less aggressive excision and postoperative radioiodine ablation of the remnant tissue. 相似文献
124.
125.
Nissen SE Nicholls SJ Wolski K Rodés-Cabau J Cannon CP Deanfield JE Després JP Kastelein JJ Steinhubl SR Kapadia S Yasin M Ruzyllo W Gaudin C Job B Hu B Bhatt DL Lincoff AM Tuzcu EM;STRADIVARIUS Investigators 《JAMA》2008,299(13):1547-1560
Context Abdominal obesity is associated with metabolic abnormalities and increased risk of atherosclerotic cardiovascular disease. However, no obesity management strategy has demonstrated the ability to slow progression of coronary disease. Objective To determine whether weight loss and metabolic effects of the selective cannabinoid type 1 receptor antagonist rimonabant reduces progression of coronary disease in patients with abdominal obesity and the metabolic syndrome. Design, Setting, and Patients Randomized, double-blinded, placebo-controlled, 2-group, parallel-group trial (enrollment December 2004-December 2005) comparing rimonabant with placebo in 839 patients at 112 centers in North America, Europe, and Australia. Interventions Patients received dietary counseling, were randomized to receive rimonabant (20 mg daily) or matching placebo, and underwent coronary intravascular ultrasonography at baseline (n = 839) and study completion (n = 676). Main Outcome Measures The primary efficacy parameter was change in percent atheroma volume (PAV); the secondary efficacy parameter was change in normalized total atheroma volume (TAV). Results In the rimonabant vs placebo groups, PAV (95% confidence interval [CI]) increased 0.25% (–0.04% to 0.54%) vs 0.51% (0.22% to 0.80%) (P = .22), respectively, and TAV decreased 2.2 mm3 (–4.09 to –0.24) vs an increase of 0.88 mm3 (–1.03 to 2.79) (P = .03). In the rimonabant vs placebo groups, imputing results based on baseline characteristics for patients not completing the trial, PAV increased 0.25% (–0.04% to 0.55%) vs 0.57% (0.29% to 0.84%) (P = .13), and TAV decreased 1.95 mm3 (–3.8 to –0.10) vs an increase of 1.19 mm3 (–0.73 to 3.12) (P = .02). Rimonabant-treated patients had a larger reduction in body weight (4.3 kg [–5.1 to –3.5] vs 0.5 kg [–1.3 to 0.3]) and greater decrease in waist circumference (4.5 cm [–5.4 to –3.7] vs 1.0 cm [–1.9 to –0.2]) (P < .001 for both comparisons). In the rimonabant vs placebo groups, high-density lipoprotein cholesterol levels increased 5.8 mg/dL (4.9 to 6.8) (22.4%) vs 1.8 mg/dL (0.9 to 2.7) (6.9%) (P < .001), and median triglyceride levels decreased 24.8 mg/dL (–35.4 to –17.3) (20.5%) vs 8.9 mg/dL (–14.2 to –1.8) (6.2%) (P < .001). Rimonabant-treated patients had greater decreases in high-sensitivity C-reactive protein (1.3 mg/dL [–1.7 to –1.2] [50.3%] vs 0.9 mg/dL [–1.4 to –0.5] [30.9%]) and less increase in glycated hemoglobin levels (0.11% [0.02% to 0.20%] vs 0.40% [0.31% to 0.49%]) (P < .001 for both comparisons). Psychiatric adverse effects were more common in the rimonabant group (43.4% vs 28.4%, P < .001). Conclusions After 18 months of treatment, the study failed to show an effect for rimonabant on disease progression for the primary end point (PAV) but showed a favorable effect on the secondary end point (TAV). Determining whether rimonabant is useful in management of coronary disease will require additional imaging and outcomes trials, which are currently under way. Trial Registration clinicaltrials.gov Identifier: NCT00124332 相似文献
126.
Bacterial biofilm and associated infections 总被引:1,自引:0,他引:1
Muhsin Jamal Wisal Ahmad Saadia Andleeb Fazal Jalil Muhammad Imran Muhammad Asif Nawaz Tahir Hussain Muhammad Ali Muhammad Rafiq Muhammad Atif Kamil 《Journal of the Chinese Medical Association》2018,81(1):7-11
Microscopic entities, microorganisms that drastically affect human health need to be thoroughly investigated. A biofilm is an architectural colony of microorganisms, within a matrix of extracellular polymeric substance that they produce. Biofilm contains microbial cells adherent to one-another and to a static surface (living or non-living). Bacterial biofilms are usually pathogenic in nature and can cause nosocomial infections. The National Institutes of Health (NIH) revealed that among all microbial and chronic infections, 65% and 80%, respectively, are associated with biofilm formation. The process of biofilm formation consists of many steps, starting with attachment to a living or non-living surface that will lead to formation of micro-colony, giving rise to three-dimensional structures and ending up, after maturation, with detachment. During formation of biofilm several species of bacteria communicate with one another, employing quorum sensing. In general, bacterial biofilms show resistance against human immune system, as well as against antibiotics. Health related concerns speak loud due to the biofilm potential to cause diseases, utilizing both device-related and non-device-related infections. In summary, the understanding of bacterial biofilm is important to manage and/or to eradicate biofilm-related diseases. The current review is, therefore, an effort to encompass the current concepts in biofilm formation and its implications in human health and disease. 相似文献
127.
128.
Nur Aziah Hanapi Ahmad Saifuddin Mohamad Arshad Jafri Malin Abdullah Tengku Sifzizul Tengku Muhammad Siti R. Yusof 《Journal of pharmaceutical sciences》2021,110(2):698-706
Neurotherapeutic potentials of Centella asiatica and its reputation to boost memory, prevent cognitive deficits and improve brain functions are widely acknowledged. The plant's bioactive compounds, i.e. asiaticoside, madecassoside and asiatic acid were reported to have central nervous system (CNS) actions, particularly in protecting the brain against neurodegenerative disorders. Hence, it is important for these compounds to cross the blood-brain barrier (BBB) to be clinically effective therapeutics. This study aimed to explore the capability of asiaticoside, madecassoside and asiatic acid to cross the BBB using in vitro BBB model from primary porcine brain endothelial cells (PBECs). Our findings showed that asiaticoside, madecassoside and asiatic acid are highly BBB permeable with apparent permeability (Papp) of 70.61 ± 6.60, 53.31 ± 12.55 and 50.94 ± 10.91 × 10?6 cm/s respectively. No evidence of cytotoxicity and tight junction disruption of the PBECs were observed in the presence of these compounds. Asiatic acid showed cytoprotective effect towards the PBECs against oxidative stress. This study reported for the first time that Centella asiatica compounds demonstrated high capability to cross the BBB, comparable to central nervous system drugs, and therefore warrant further development as therapeutics for the treatment of neurodegenerative diseases. 相似文献
129.
Farrukh Aslam Khalid Muhammad Younas Mehrose Muhammad Saleem Muhammad Amin Yousaf Abdul Malik Mujahid Saif Ur Rehman Sania Ahmad Moazzam Nazeer Tarar 《Burns : journal of the International Society for Burn Injuries》2019,45(1):69-75
The treatment of keloid and hypertrophic scar is challenging with no universally accepted mode for permanent ablation. Conventional therapies yield unpredictable results, significant complications and require elaborate hardware.